Zhejiang Provincial People's Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1978-01-01
- Employees
- -
- Market Cap
- -
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT06722911
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC
Phase 2
Not yet recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: Pembrolizumab+Flutamide
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT06694350
Evaluation of Clinical Efficacy and Prognosis in Patients with Hypertrophic Obstructive Cardiomyopathy Through Hemodynamic Modeling Reconstructed by CT
- Conditions
- Hypertrophic Cardiomyopathy (HCM)
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06683872
- Locations
- 🇨🇳
Zhejiang Province People's Hospital, Hangzhou, Zhejiang, China
The Effectiveness of Pharmaceutical Service for INPATDRP
Not Applicable
Not yet recruiting
- Conditions
- Drug Related Problem
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT06674512
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Provincial, China
Multicentre Clinical Study of Ultra-Fast-Track Anaesthesia for Minimally Invasive Heart Valve Surgery
Not Applicable
Not yet recruiting
- Conditions
- Heart Valve DiseasesEnhanced Recovery After Surgery
- Interventions
- Procedure: Ultra-Fast-Track Cardiac Anesthesia(UFTCA)Procedure: conventional general anesthesia (CGA)
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 1200
- Registration Number
- NCT06541483
Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia
Phase 4
Recruiting
- Conditions
- Sarcopenia
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 450
- Registration Number
- NCT06537115
- Locations
- 🇨🇳
The First People's Hospital of Chun'an County, Hangzhou, Zhejiang, China
🇨🇳Dinghai Central Hospital of Zhoushan City, Zhoushan, Zhejiang, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Phase 2
Recruiting
- Conditions
- Pancreas CancerSCLCColorectal CancerTNBC - Triple-Negative Breast CancerNSCLCDLBCL - Diffuse Large B Cell LymphomaSquamous Cell Carcinoma of Head and Neck
- Interventions
- Biological: Mirabegron
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 260
- Registration Number
- NCT06534762
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
Phase 3
Recruiting
- Conditions
- Alzheimer's Disease
- Interventions
- Procedure: Deep Cervical lymphatlc-Venous Anastomosis Surgery
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06530732
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 848
- Registration Number
- NCT06530537
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies
Phase 1
Not yet recruiting
- Conditions
- Solid TumorCancerHematologic Malignancy
- Interventions
- Drug: Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06528249
© Copyright 2025. All Rights Reserved by MedPath